Why ClearPoint Neuro, Inc.’s (CLPT) Stock Is Down 12.99%
As of Thursday, November 05, ClearPoint Neuro, Inc.’s CLPT share price has dipped by 12.99%, which has investors questioning if this is right time to buy.Jenna Brashear
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Rosalio Madrigal
Jenna Brashear
Jenna Brashear
Michael Rose
| Share Statistics | CLPT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $275.7 | $402.1 | 32% |
|
| Shares Out (Mil) | 31.0 | 40.6 | 38% |
|
| Institutional Ownership | 86.8% | 83.5% | 55% |
|
| Float (Mil) | 26.1 | 35.2 | 33% |
|
| Beta | 1.29 | 0.85 | 75% |
|
| Avg Daily Volume (000s) | 868 | 373 | 65% |
|
| Price Change (52-week) |
(49.4%) | 63.1% | 20% |
|
| Growth | CLPT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 23.7% | 11.8% | 85% |
|
| Net Income (5yr) | (30.3%) | (5.6%) | 14% |
|
| EPS (5yr) | (16.1%) | 10.6% | 17 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 0.9% | (15.6%) | 65% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($0.230) | ($1.165) | ($0.920) | |
| Month Ago EPS | ($0.295) | ($1.305) | ($1.195) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 3 | |
| Three Months Ago EPS | ($0.303) | ($1.323) | ($1.107) | |
| Year/Year Chg | (4.6%) | 29.2% | (4.7%) | |
| Financials | CLPT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $46 | $127 | 19% |
|
| Net Income (TTM) (Mil) | ($36) | ($9) | 19% |
|
| EPS (TTM) | ($1.209) | ($0.300) | 19% |
|
| Operating Cash Flow (TTM) (Mil) | ($32) | ($1) | 12% |
|
| Net Cash Flow (TTM) (Mil) | $9 | $2 | 56% |
|
| Long-Term Debt (Q1) (Mil) | $74 | $27 | 42% |
|
| Enterprise Value (Q1) (Mil) | $370 | $390 | 31% |
|
| Valuation | CLPT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 10.12 | 2.54 | 92% |
|
| P/E | na | 26.2 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.4 | na |
|
| Ratios | CLPT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 61.4% | 59.5% | 74% |
|
| Net Margin | (79.4%) | (4.6%) | 9% |
|
| ROA | (41.8%) | (10.8%) | 13% |
|
| ROE | (167.5%) | (9.4%) | 5% |
|
| Liabilities to Assets | 75.8% | 46.0% | 72% |
|
| F-Score | 3 | 4 | 18% |
|
ClearPoint Neuro, Inc. did not pass any screens on 11/6/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors